Strategic Development of Live Biotherapeutic Products to Prevent Clostridioides difficile Infections
Overview
Clostridioides difficile infection (CDI) is a significant cause of healthcare-associated diarrhea with high recurrence rates. This study employed a computational pipeline analyzing metagenomic datasets to identify protective microbial strains for designing live biotherapeutic products (LBPs) targeting CDI prevention, highlighting strains such as Dorea formicigenerans and Faecalibacterium prausnitzii.
Background
CDI affects approximately 500,000 patients annually in the US, with about 25% experiencing recurrence after antibiotic treatment. Fecal microbiota transplantation (FMT) has shown efficacy in recurrent CDI but carries risks including pathogen transmission and unclear mechanisms. Recently approved fecal microbiota products offer alternatives but lack predefined microbial compositions. Strain-level analysis is crucial due to variability in bacterial strain pathogenicity and probiotic potential. Metagenome-assembled genomes (MAGs) enable identification of uncultured microbes beyond reference databases, facilitating rational LBP design.
Data Highlights
The study analyzed metagenomic sequencing data from three cohorts: Beth Israel Deaconess Medical Center (n=104), Verma cohort (n=43), and Human Microbiome Project (n=94). A total of 7,776 MAGs were reconstructed and de-replicated into 3,741 nonredundant MAGs (nrMAGs) with ≥50% completeness and ≤5% contamination. Multiple protective nrMAGs were identified, including strains from Dorea formicigenerans, Oscillibacter welbionis, and Faecalibacterium prausnitzii, which correlated with FMT success.
Key Findings
CDI recurrence occurs in approximately 25% of cases after antibiotic treatment, highlighting the need for alternative preventive strategies.
FMT is effective but has limitations including safety concerns and undefined microbial composition.
Computational reconstruction of 3,741 nonredundant MAGs from CDI-related cohorts enabled strain-level identification of protective microbes.
Protective strains identified include Dorea formicigenerans, Oscillibacter welbionis, and Faecalibacterium prausnitzii, which are implicated in successful FMT outcomes.
Most top protective strains were validated by previous studies, supporting their potential role in LBP development.
The study provides a framework for rational design of LBPs targeting CDI and potentially other enteric infections.
Clinical Implications
The identification of specific protective bacterial strains offers a promising avenue for developing targeted LBPs to prevent CDI recurrence, potentially reducing reliance on antibiotics and the risks associated with FMT. Clinicians should consider emerging LBP therapies as adjuncts or alternatives to current treatments, especially for patients at high risk of CDI recurrence.
Conclusion
This study demonstrates a novel computational approach to identify microbial strains protective against CDI, facilitating the rational design of live biotherapeutic products. Such targeted therapies may improve prevention strategies for CDI and enhance patient outcomes.
References
FDA 2022 -- Approval of Rebyota and Vowst for rCDI prevention
MetaWRAP 2019 -- Metagenomic assembly and binning pipeline
dRep 2017 -- De-replication of metagenome-assembled genomes
